By Counterforce Health Team in Enhertu (fam-trastuzumab deruxtecan-nxki) —

Do You Qualify for Enhertu Coverage by UnitedHealthcare in Washington? Decision Tree & Next Steps

Answer Box

UnitedHealthcare requires prior authorization (PA) for Enhertu (fam-trastuzumab deruxtecan-nxki) in Washington, mandating HER2-positive biomarker testing, specific cancer diagnoses, and evidence of prior HER2-targeted therapy failure. Submit PA via the UnitedHealthcare Provider Portal with pathology reports, treatment history, and oncologist letter. If denied, Washington residents can appeal internally (60 days), then request external review through an Independent Review Organization (IRO) within 60 days. First step: verify your HER2 status and gather prior therapy documentation.

Table of Contents

  1. How to Use This Decision Tree
  2. Eligibility Triage: Do You Qualify?
  3. If "Likely Eligible": Document Checklist
  4. If "Possibly Eligible": Tests to Request
  5. If "Not Yet": Alternatives to Discuss
  6. If Denied: Appeal Path Chooser
  7. Coverage at a Glance
  8. Common Denial Reasons & Fixes
  9. Washington Appeals Process
  10. FAQ

How to Use This Decision Tree

This guide helps patients and clinicians navigate UnitedHealthcare's Enhertu coverage requirements in Washington state. Start with the eligibility triage below to determine your likelihood of approval, then follow the corresponding action steps. Each section includes specific documentation requirements and timelines.

Note: This guide applies to UnitedHealthcare commercial plans and Medicare Advantage. Medicaid (Apple Health) patients should consult their managed care plan's formulary.

Eligibility Triage: Do You Qualify?

✅ Likely Eligible

  • HER2-positive breast cancer (metastatic): Confirmed HER2 3+ by IHC or ISH+ by FISH, with prior trastuzumab-based therapy failure
  • HER2-mutant NSCLC (metastatic): Documented HER2 mutation via comprehensive genomic profiling, with prior systemic therapy
  • HER2-positive gastric/GEJ cancer (metastatic): HER2 3+ or ISH+, with prior trastuzumab treatment
  • Oncologist prescriber and baseline pulmonary assessment completed

⚠️ Possibly Eligible

  • HER2-low breast cancer (IHC 1+ or 2+/ISH-) with hormone receptor-positive, endocrine-refractory disease
  • Recent HER2 testing but missing comprehensive prior therapy documentation
  • Adequate performance status but baseline pulmonary function not yet assessed

❌ Not Yet Eligible

  • HER2-negative disease (IHC 0, ISH-)
  • No prior HER2-targeted therapy (step therapy required)
  • Active interstitial lung disease (ILD) or severe pulmonary compromise
  • Non-oncologist prescriber

If "Likely Eligible": Document Checklist

Gather these documents before submitting your PA request:

Required Clinical Documentation

  • Pathology report with HER2 testing methodology (IHC 3+ or ISH+)
  • Treatment history with dates, duration, and outcomes of prior HER2-targeted therapies
  • Staging workup confirming metastatic disease
  • ICD-10 diagnosis codes (e.g., C50.911 for breast cancer, C78.00 for lung metastases)
  • Baseline pulmonary assessment (chest CT, oxygen saturation, consider PFTs)
  • Performance status documentation (ECOG 0-2 preferred)

Submission Process

  1. Access portal: Log into UnitedHealthcare Provider Portal
  2. Submit PA: Include medical necessity letter citing NCCN guidelines and FDA labeling
  3. Track status: Standard review takes 5-15 business days; expedited (72 hours) for urgent cases
  4. Call if needed: OptumRx at 866-889-8054 for status updates

If "Possibly Eligible": Tests to Request

Additional Testing Needed

  • Comprehensive genomic profiling if HER2 mutation status unclear (NSCLC patients)
  • Updated HER2 testing on metastatic tissue if >1 year since last assessment
  • Baseline pulmonary function tests in consultation with pulmonology
  • Complete treatment history documentation from all prior oncologists

Timeline to Re-apply

  • Allow 2-3 weeks for additional testing results
  • Resubmit PA within 30 days of receiving new documentation
  • Consider expedited review if treatment delay poses clinical risk

If "Not Yet": Alternatives to Discuss

Step Therapy Options

UnitedHealthcare typically requires these alternatives first:

Cancer Type Preferred First-Line Alternative Options
HER2+ Breast Trastuzumab biosimilars (Kanjinti, Trazimera), pertuzumab T-DM1, tucatinib combinations
HER2+ Gastric Trastuzumab + chemotherapy Ramucirumab, paclitaxel
HER2-mutant NSCLC Platinum-based chemotherapy Osimertinib (if EGFR+), immunotherapy

Exception Request Strategy

  • Document contraindications or intolerances to preferred agents
  • Provide evidence of rapid disease progression requiring immediate Enhertu
  • Cite patient-specific factors (age, comorbidities, prior toxicities)

If Denied: Appeal Path Chooser

Level 1: Internal Appeal (First 60 Days)

  • Submit to: UnitedHealthcare internal review department
  • Timeline: 30 days for pre-service, 60 days for post-service
  • Required: Medical necessity letter, complete clinical records, denial letter
  • Expedited: 72 hours if delay jeopardizes health

Level 2: Peer-to-Peer Review

  • Who requests: Prescribing oncologist only
  • Process: Direct discussion with UHC medical director
  • Timeline: Schedule within 5 business days of denial
  • Preparation: NCCN guideline citations, real-world evidence, patient-specific factors

Level 3: External Review (Washington IRO)

  • Eligibility: After exhausting internal appeals
  • Timeline: Submit within 60 days of final internal denial
  • Process: Independent Review Organization (IRO) assigned by Washington Office of Insurance Commissioner
  • Decision: Binding on UnitedHealthcare if approved
  • Contact: Washington Office of Insurance Commissioner at 1-800-562-6900

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all Enhertu prescriptions UHC Provider Portal UHC PA Requirements
HER2 Testing IHC 3+ or ISH+ required Pathology report FDA Label
Step Therapy Prior HER2-targeted therapy failure Treatment records OptumRx Criteria
Oncologist Prescriber Board-certified oncologist required Provider credentialing UHC Policy
Site of Care Outpatient infusion center Network directory UHC Provider Portal
Appeals Deadline 60 days from denial Denial letter RCW 48.43.535

Common Denial Reasons & Fixes

Denial Reason How to Overturn Required Documents
Missing HER2 status Submit complete pathology report Original pathology with IHC/FISH results
Insufficient prior therapy Document step therapy failures Treatment dates, outcomes, intolerance records
ILD risk concerns Provide baseline pulmonary assessment Chest CT, PFTs, monitoring plan
Non-formulary status Request formulary exception Medical necessity letter, alternative failures
Site of care restriction Confirm network infusion center Provider directory verification

Washington Appeals Process

Washington state provides robust consumer protections for insurance denials through RCW 48.43.535.

Internal Appeals

  1. Submit written request to UnitedHealthcare within 60 days
  2. Include new information if available
  3. Track timeline: 30 days for pre-service, 60 days for post-service decisions

External Review (IRO)

  1. Request external review within 60 days of final internal denial
  2. Submit to insurer who forwards to Washington OIC
  3. IRO assignment: State-certified Independent Review Organization
  4. Timeline: 20 days for standard review, 72 hours for expedited
  5. Decision: Binding on UnitedHealthcare if approved
From our advocates: We've seen Washington patients successfully overturn Enhertu denials by providing comprehensive HER2 testing documentation and detailed prior therapy records. The key is demonstrating clear medical necessity with complete clinical evidence. While outcomes vary, thorough documentation significantly improves appeal success rates.

Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals. Our platform analyzes denial letters and plan policies to draft point-by-point rebuttals aligned with each insurer's specific requirements, helping patients access critical medications like Enhertu.

FAQ

How long does UnitedHealthcare PA take in Washington? Standard prior authorization takes 5-15 business days. Expedited review (72 hours) is available for urgent cases where treatment delay could jeopardize health.

What if Enhertu is non-formulary on my plan? Request a formulary exception with medical necessity documentation. Provide evidence that formulary alternatives have failed or are contraindicated.

Can I request an expedited appeal in Washington? Yes, if delay in treatment would seriously jeopardize your life, health, or ability to regain maximum function. Document urgency in your appeal request.

Does step therapy apply if I failed treatments in another state? Yes, UnitedHealthcare recognizes prior therapy failures regardless of where they occurred. Provide complete treatment records from all providers.

What's the success rate for external review in Washington? While specific Enhertu data isn't available, external review success rates typically range from 40-60% nationally when complete clinical documentation is provided.

How much does Enhertu cost without insurance? Enhertu costs approximately $2,440 per 100mg vial. Total cycle costs depend on patient weight and dosing schedule. Patient assistance programs may be available.

Can I get help with my appeal in Washington? Yes, contact the Washington Office of Insurance Commissioner Consumer Advocacy line at 1-800-562-6900 for free assistance with appeals.

What if my plan is self-funded through my employer? Self-funded ERISA plans may not be subject to Washington state external review. Contact the U.S. Department of Labor for ERISA plan appeals guidance.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions vary by individual plan and clinical circumstances. Always consult with your healthcare provider and insurance plan for specific coverage determination. For personalized assistance with complex appeals, consider working with specialists like Counterforce Health who can help navigate insurance requirements and develop targeted appeal strategies.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.